DISCOVER YOUR OWN WAY WITH PATH TO INDEPENDENCE™

A personalized administration training program for CINRYZE offered by OnePath®
ARE YOU A CANDIDATE FOR SELF-ADMINISTRATION?

Learning how to administer is a choice for you, your caregiver(s), and your doctor to consider. Talk to your doctor to see if the Path to Independence™ program is right for you. Your caregiver(s) or family members are also eligible for administration training through the program. This can be an option in case you are unable to administer therapy yourself.

Even if self-administration is not right for you, other options are available. Speak with your doctor to determine the administration option that is best for your lifestyle.

You and your caregiver(s) should only administer after being trained by a healthcare provider.

**Indication**

CINRYZE® (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in children (6 years of age and older), teenagers, and adults with Hereditary Angioedema (HAE).

**Important Safety Information**

You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.

Please see additional Important Safety Information on adjacent pages. For additional safety information, please click here for Full Prescribing Information and discuss with your doctor.
The Path to Independence program is designed to help eligible people with HAE, family members, and caregivers learn how to administer CINRYZE® (C1 esterase inhibitor [human]). The program has a network of specially trained infusion nurses who are available to help people with HAE learn proper infusion technique, reinforce storage and disposal practices, and provide ongoing support throughout the infusion training process.

You and your caregiver(s) should only administer after being trained by a healthcare provider.

Is offered to eligible people with HAE enrolled in OnePath® at no cost. People with HAE will not be responsible for any out-of-pocket charges associated with the program.

Offers training to people with HAE and their caregiver(s), so they can have a support network even after the training sessions have finished.

**Important Safety Information (cont’d)**

Tell your healthcare provider about all of your medical conditions, including if you:

- have an indwelling catheter/access device in one of your veins.
- have a history of blood clots, heart disease, or stroke.
- are taking birth control pills or androgens.
- are pregnant or planning to become pregnant. It is not known if CINRYZE can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if CINRYZE passes into your milk and if it can harm your baby.

Please see additional Important Safety Information on adjacent pages. For additional safety information, please click here for Full Prescribing Information and discuss with your doctor.
SELF-ADMINISTRATION TRAINING

Once you are enrolled in the program, a Path to Independence™ infusion nurse will visit you and begin the training process. The goal of this program is to help you and/or your caregiver(s) learn how to administer safely, proficiently, and with confidence. An infusion nurse will work with you individually and throughout the process. They are here to support you throughout your training!

• The infusion nurse will train you and/or your caregiver(s) in:
  — Proper preparation of CINRYZE® (C1 esterase inhibitor [human])
  — IV infusion techniques
  — Appropriate methods for storage, handling, and disposal of CINRYZE

• Your dedicated Patient Support Manager (PSM) will help support self-administration training by:
  — Coordinating in-home injection training with the infusion nurse
  — Ordering more medication and infusion supplies from a specialty pharmacy
  — Ensuring a training summary is sent to your doctor once your training is complete

You and your caregiver(s) should only administer after being trained by a healthcare provider.

Important Safety Information (cont’d)

Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms:

• wheezing
• difficulty breathing
• chest tightness
• turning blue (look at lips and gums)
• fast heartbeat
• swelling of the face
• faintness
• rash
• hives

Please see additional Important Safety Information on adjacent pages. For additional safety information, please click here for Full Prescribing Information and discuss with your doctor.
ONGOING SUPPORT

Typically, it takes 3 to 5 visits for people to become comfortable with the infusion process. Even after you have been trained to administer CINRYZE® (C1 esterase inhibitor [human]), you can still receive periodic visits from an infusion nurse who can give you a refresher on anything you have learned throughout your training. During these visits the infusion nurse will:

• Answer questions that come up through your experience with administration
• Provide feedback and guidance on infusion techniques
• Serve as a resource about the infusion process and the importance of staying on track with your therapy with CINRYZE

You can schedule appointments with the nurse at a time that is convenient for you—including weekends and evenings.

“I like being able to self-administer, because I can do my infusions at home, at work, or when traveling. I don’t have to worry about the infusion center being closed. I like having more control of my schedule that way.

—A real person with HAE

Important Safety Information (cont’d)

Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms:

• pain and/or swelling of an arm or leg with warmth over the affected area
• discoloration of an arm or leg
• unexplained shortness of breath
• chest pain or discomfort that worsens on deep breathing
• unexplained rapid heart rate
• numbness or weakness on one side of the body

Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see additional Important Safety Information on adjacent pages. For additional safety information, please click here for Full Prescribing Information and discuss with your doctor.
If you would like to learn more about the Path to Independence program or have any questions, call your OnePath® Patient Support Manager at 1-866-888-0660.

Important Safety Information (cont’d)

The most common side effects seen with CINRYZE® (C1 esterase inhibitor [human]) were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional safety information, please click here for Full Prescribing Information and discuss with your doctor.